ArticleBMC cell biology2003
Rapid de-localization of actin leading edge components with BDM treatment.
Article in BMC cell biology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Rapid nucleus-scale reorganization of chromatin in neurons enables transcriptional adaptation for memory consolidation.PloS one · 2021Article
- Article
- Arp2/3 complex inhibition radically alters lamellipodial actin architecture, suspended cell shape, and the cell spreading process.Molecular biology of the cell · 2015Article
- Broadening the spectrum of actin-based protrusive activity mediated by Arp2/3 complex-facilitated polymerization: motility of cytoplasmic ridges and tubular projections.Cytoskeleton (Hoboken, N.J.) · 2014Article
- Nuclear myosin 1c facilitates the chromatin modifications required to activate rRNA gene transcription and cell cycle progression.PLoS genetics · 2013Article
- Herpesviral replication compartments move and coalesce at nuclear speckles to enhance export of viral late mRNA.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Article
- Divergent roles of RelA and c-Rel in establishing chromosomal loops upon activation of the Igkappa gene.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Structure and dynamics of an Arp2/3 complex-independent component of the lamellipodial actin network.Cell motility and the cytoskeleton · 2009Article
- Mechanical and spatial determinants of cytoskeletal geodesic dome formation in cardiac fibroblasts.Integrative biology : quantitative biosciences from nano to macro · 2009Article
- Cytoskeleton reorganization in influenza hemagglutinin-initiated syncytium formation.Biochimica et biophysica acta · 2009Article
- Nuclear myosin I acts in concert with polymeric actin to drive RNA polymerase I transcription.Genes & development · 2008Article
- A unique role for nonmuscle myosin heavy chain IIA in regulation of epithelial apical junctions.PloS one · 2007Article
- 2,3-Butanedione monoxime increases sensitivity to Nikkomycin Z in the budding yeastWorld journal of microbiology & biotechnology · 2006Article
- Actin and non-muscle myosin II facilitate apical exocytosis of tear proteins in rabbit lacrimal acinar epithelial cells.Journal of cell science · 2005Article
- Redundant mechanisms for anaphase chromosome movements: crane-fly spermatocyte spindles normally use actin filaments but also can function without them.Protoplasma · 2005Article
- Role for actin filament turnover and a myosin II motor in cytoskeleton-driven disassembly of the epithelial apical junctional complex.Molecular biology of the cell · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
background2,3-butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show that BDM does not inhibit any non-muscle myosins so far tested, including nm-myosinII, prompting the question, how were these process affected in BDM studies?
resultsWe have found that treatment of mammalian cells with BDM for only 1 min blocks actin incorporation at the leading edge in a permeabilized cell system. We show that inhibition of actin incorporation occurs through de-localization of leading edge proteins involved in actin polymerization--the Arp2/3 complex, WAVE, and VASP--that de-localize concomitantly with the leading edge actin network.
conclusionDe-localization of actin leading edge components by BDM treatment is a newly described effect of this compound. It may explain many of the results previously ascribed to inhibition of non-muscle myosinII by BDM, particularly in studies of leading edge dynamics. Though this effect of BDM is intriguing, future studies probing actin dynamics at the leading edge should use more potent and specific inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.